Using Machine Learning to Identify Responders to TACE or HAIC for uHCC

Browse trials for

• Carcinoma, Hepatocellular 3,182

Keywords

• hepatocellular carcinoma
• transarterial chemoembolization
• hepatic arterial infusion chemotherapy
• machine learning

Carcinoma, Hepatocellular

3,182 studies on the registry are indexed under Carcinoma, Hepatocellular; 954 are open to participants now.

This study's enrollment of 3,000 is above the median of 200 across 754 observational studies indexed under Carcinoma, Hepatocellular.

Lead sponsor

First Affiliated Hospital, Sun Yat-Sen University is the lead sponsor of 155 studies on the registry; 51 are open to participants now.

Study population

Groups and cohorts

• TACE group

  Patients with unresectable HCC treated with transarterial chemoembolization

  Procedure: Transarterial chemoembolization (TACE)

• HAIC group

  Patients with unresectable HCC treated with hepatic arterial infusion chemotherapy

  Procedure: hepatic arterial infusion chemotherapy (HAIC)

Interventions

• ProcedureTransarterial chemoembolization (TACE)

  1

• Procedurehepatic arterial infusion chemotherapy (HAIC)

  1

Primary outcomes

1. Overall survival

   Time interval from date of initial treatment until the date of death from any cause, whichever came first, assessed up to 24 months

   Time frame: From date of initial treatment until the date of death from any cause, whichever came first, assessed up to 24 months

Secondary outcomes

1. Progression free survival

   Time interval from date of initial treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

   Time frame: From date of initial treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

2. Tumor response

   Defined as the proportion of patients achieving complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD) according to mRECIST criteria.

   Time frame: From date of initial treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

Individual participant data

Plan to share: No — This study utilizes existing clinical and imaging data collected as part of routine medical care. The dataset contains detailed and potentially re-identifiable patient information, including medical images, clinical records, and treatment outcomes. Due to institutional data privacy policies, ethical restrictions related to patient confidentiality, and the lack of broad consent from participants for data sharing beyond the scope of this specific research, we are unable to publicly share individual participant data. All data will be stored securely within the hospital's internal research database, and access will be restricted to the study investigators for analysis purposes only. Requests for aggregated or de-identified results may be considered upon reasonable inquiry to the corresponding author, subject to institutional review and compliance with applicable regulations.